» Articles » PMID: 25741387

Concomitant Downregulation of the Imprinted Genes DLK1 and MEG3 at 14q32.2 by Epigenetic Mechanisms in Urothelial Carcinoma

Overview
Publisher Biomed Central
Specialty Genetics
Date 2015 Mar 6
PMID 25741387
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The two oppositely imprinted and expressed genes, DLK1 and MEG3, are located in the same gene cluster at 14q32. Previous studies in bladder cancer have suggested that tumor suppressor genes are located in this region, but these have not been identified.

Results: We observed that both DLK1 and MEG3 are frequently silenced in urothelial cancer tissues and cell lines. The concomitant downregulation of the two genes is difficult to explain by known mechanisms for inactivating imprinted genes, namely deletion of active alleles or epitype switching. Indeed, quantitative PCR revealed more frequent copy number gains than losses in the gene cluster that were, moreover, consistent within each sample, excluding gene losses as the cause of downregulation. Instead, we observed distinctive epigenetic alterations at the three regions controlling DLK1 and MEG3 expression, namely the DLK1 promoter; the intergenic (IG) and MEG3 differentially methylated regions (DMRs). Bisulfite sequencing and pyrosequencing revealed novel patterns of DNA methylation in tumor cells, which were distinct from that of either paternal allele. Furthermore, chromatin immunoprecipitation demonstrated loss of active and gain of repressive histone modifications at all regulatory sequences.

Conclusions: Our data support the idea that the main cause of the prevalent downregulation of DLK1 and MEG3 in urothelial carcinoma is epigenetic silencing across the 14q32 imprinted gene cluster, resulting in the unusual concomitant inactivation of oppositely expressed and imprinted genes.

Citing Articles

A review of current evidence about lncRNA MEG3: A tumor suppressor in multiple cancers.

Xu J, Wang X, Zhu C, Wang K Front Cell Dev Biol. 2022; 10:997633.

PMID: 36544907 PMC: 9760833. DOI: 10.3389/fcell.2022.997633.


Increased copy number of imprinted genes in the chromosomal region 20q11-q13.32 is associated with resistance to antitumor agents in cancer cell lines.

Krushkal J, Vural S, Jensen T, Wright G, Zhao Y Clin Epigenetics. 2022; 14(1):161.

PMID: 36461044 PMC: 9716673. DOI: 10.1186/s13148-022-01368-7.


Essential Role of the 14q32 Encoded miRNAs in Endocrine Tumors.

Krokker L, Patocs A, Butz H Genes (Basel). 2021; 12(5).

PMID: 34066712 PMC: 8151414. DOI: 10.3390/genes12050698.


LncRNA -Derived Accelerates the Invasion of Extravillous Trophoblast Cells by Inhibiting and Subsequently Activating Matrix Metalloproteinases.

Ogoyama M, Ohkuchi A, Takahashi H, Zhao D, Matsubara S, Takizawa T Int J Mol Sci. 2021; 22(3).

PMID: 33513878 PMC: 7866107. DOI: 10.3390/ijms22031237.


Dysregulation of ncRNAs located at the DLK1‑DIO3 imprinted domain: involvement in urological cancers.

Li J, Shen H, Xie H, Ying Y, Jin K, Yan H Cancer Manag Res. 2019; 11:777-787.

PMID: 30697070 PMC: 6339654. DOI: 10.2147/CMAR.S190764.


References
1.
Kavanagh E, Joseph B . The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011; 1816(1):50-6. DOI: 10.1016/j.bbcan.2011.03.002. View

2.
Kapoor-Vazirani P, Kagey J, Powell D, Vertino P . Role of hMOF-dependent histone H4 lysine 16 acetylation in the maintenance of TMS1/ASC gene activity. Cancer Res. 2008; 68(16):6810-21. PMC: 2585755. DOI: 10.1158/0008-5472.CAN-08-0141. View

3.
Hoffmann M, Florl A, Seifert H, Schulz W . Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer. 2004; 114(3):406-13. DOI: 10.1002/ijc.20749. View

4.
Xi L, Fondufe-Mittendorf Y, Xia L, Flatow J, Widom J, Wang J . Predicting nucleosome positioning using a duration Hidden Markov Model. BMC Bioinformatics. 2010; 11:346. PMC: 2900280. DOI: 10.1186/1471-2105-11-346. View

5.
Shahbazian M, Grunstein M . Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem. 2007; 76:75-100. DOI: 10.1146/annurev.biochem.76.052705.162114. View